NewsBenzingaEquillium Doses First Patient In Australia In Its Phase 1 Clinical Study Of EQ504 To Treat Serious Inflammatory Diseases Equillium Doses First Patient In Australia In Its Phase 1 Clinical Study Of EQ504 To Treat Serious Inflammatory Diseases Benzinga 2026.10.26 12:31 (GMT+0) Open on Benzinga Other news NVIDIA Interim CEO Colette Kress Says Vera Rubin Is Off To An Explosive Start, Our Roadmap Is On Track And Our Ambition Has Never Been Greater Here’s How Much You Would Have Made Owning Marvell Technology Stock In The Last 20 Years NVIDIA Sees Q4 Sales $126.100B-$133.900B vs $125.163B Est NVIDIA Q3 Adj. EPS $2.68 Beats $2.48 Estimate, Sales $115.844B Beat $109.080B Estimate Dolby Laboratories Sees Q1 GAAP EPS $0.01-$0.16 vs $0.76 Est Dolby Laboratories Sees Q1 Adj EPS $0.41-$0.56 vs $1.12 Est; Sees Sales $285.000M-$305.000M vs $359.329M Est
NVIDIA Interim CEO Colette Kress Says Vera Rubin Is Off To An Explosive Start, Our Roadmap Is On Track And Our Ambition Has Never Been Greater
Dolby Laboratories Sees Q1 Adj EPS $0.41-$0.56 vs $1.12 Est; Sees Sales $285.000M-$305.000M vs $359.329M Est